OKYO PHARMA LIMITED

Inactive Instrument

Highlights OKYO Pharma Limited London S.E.

Equities

OKYO

GG00BMFG5F62

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	Mar. 22	CI
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	Mar. 20	CI
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain	Feb. 09	MT
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	Feb. 09	CI
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease	Jan. 08	CI
Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	Dec. 04	CI
Okyo Pharma Limited Announces Filing of an Investigational New Drug Application for Ok-101 to Treat Neuropathic Corneal Pain	23-10-09	CI
OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease	23-10-05	CI
Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease	23-09-08	CI
OKYO Pharma Limited Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to Treat Dry Eye Disease	23-08-30	CI
OKYO Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-08-15	CI
OKYO Pharma Plans to Initiate Mid-Stage Trial in Neuropathic Corneal Pain; Shares Rise	23-07-28	MT
OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain	23-07-28	CI
OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease	23-06-06	CI
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease	22-12-22	CI
OKYO Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-08-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer